Reacción #48786

ord-92dde1c0049c4877a8fae7acf59b2742

Ecuación de reacción

C[C@@H](CO[Si](C)(C)C(C)(C)C)Oc1cc(O)cc(C(=O)Nc2ccn(C)n2)c1
3-((1S)-2-{[tert-butyl(dimethyl)silyl]oxy}-1-methylethyloxy)-5-hydroxy-N-(1-methyl-1H-pyrazol-3-yl)benzamide
OB(O)c1cc(F)cc(F)c1
3,5-difluorophenylboronic acid
CCN(CC)CC
triethylamine
C[C@@H](CO)Oc1cc(Oc2cc(F)cc(F)c2)cc(C(=O)Nc2ccn(C)n2)c1
title compound
Rendimiento 22.3%
C[C@@H](CO)Oc1cc(Oc2cc(F)cc(F)c2)cc(C(=O)Nc2ccn(C)n2)c1
3-[(3,5-Difluorophenyl)oxy]-5-{[(1S)-2-hydroxy-1-methylethyl]oxy}-N-(1-methyl-1H-pyrazol-3-yl)benzamide
Rendimiento 22.3%

Disolventes

Condiciones de reacción

Condiciones detalladas
See reaction.notes.procedure_details.

Tratamiento posterior

  1. 1
    FiltraciónThe reaction mixture was filtered
  2. 2
    Lavadowashed with DCM (2×10 mL)
  3. 3
    Otroevaporated in vacuo
  4. 4
    Otrothe residual oil partitioned between ethyl acetate (25 mL) and 1M hydrochloric acid (10 mL)
  5. 5
    OtroThe ethyl acetate layer was separated
  6. 6
    Lavadowashed sequentially with aqueous sodium hydrogen carbonate solution and brine
  7. 7
    Secadodried (MgSO4)
  8. 8
    Otroevaporated to a residue which
  9. 9
    Otrowas chromatographed by preparative HPLC on C18 reversed phase

Procedimiento

A solution of 3-((1S)-2-{[tert-butyl(dimethyl)silyl]oxy}-1-methylethyloxy)-5-hydroxy-N-(1-methyl-1H-pyrazol-3-yl)benzamide (202 mg, 0.5 mmol), 3,5-difluorophenylboronic acid (156 mg, 1.0 mmol), copper (II) acetate (182 mg, 1.0 mmol), triethylamine (252 mg, 2.5 mmol) and freshly activated 4 Å molecular sieves (1.5 g) in DCM (10 mL) was stirred at ambient temperature and under ambient atmosphere for 64 hours. The reaction mixture was filtered, washed with DCM (2×10 mL), evaporated in vacuo and the residual oil partitioned between ethyl acetate (25 mL) and 1M hydrochloric acid (10 mL). The ethyl acetate layer was separated, washed sequentially with aqueous sodium hydrogen carbonate solution and brine, dried (MgSO4), and evaporated to a residue which was chromatographed by preparative HPLC on C18 reversed phase using 5-95% acetonitrile (+0.2% TFA) in water (+0.2% TFA) as eluant to give the title compound (45 mg).

Fuente

DOI: 10.6084/m9.figshare.5104873.v1Patente: US07745475B2uspto-grants-2010_06